Analysts expect Histogenics Corp (NASDAQ:HSGX) to post ($0.31) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Histogenics’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.33). Histogenics posted earnings per share of ($1.60) during the same quarter last year, which indicates a positive year-over-year growth rate of 80.6%. The business is scheduled to announce its next earnings results on Thursday, March 15th.
On average, analysts expect that Histogenics will report full-year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.22) to ($1.02). For the next financial year, analysts forecast that the company will post earnings of ($0.82) per share, with EPS estimates ranging from ($1.02) to ($0.62). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Histogenics.
A number of equities research analysts have commented on HSGX shares. HC Wainwright set a $4.00 price target on Histogenics and gave the company a “buy” rating in a report on Wednesday, December 27th. Zacks Investment Research cut Histogenics from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th. ValuEngine raised Histogenics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, Canaccord Genuity reissued a “buy” rating and set a $4.00 price target on shares of Histogenics in a report on Thursday, December 21st.
Histogenics (HSGX) remained flat at $$2.59 during trading hours on Tuesday. 17,903 shares of the stock were exchanged, compared to its average volume of 124,309. Histogenics has a twelve month low of $1.55 and a twelve month high of $3.13.
Several institutional investors have recently modified their holdings of the company. Sabby Management LLC grew its position in shares of Histogenics by 98.3% during the fourth quarter. Sabby Management LLC now owns 955,060 shares of the biotechnology company’s stock valued at $1,958,000 after purchasing an additional 473,393 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Histogenics by 54.8% during the fourth quarter. Renaissance Technologies LLC now owns 242,500 shares of the biotechnology company’s stock valued at $497,000 after purchasing an additional 85,800 shares in the last quarter. Deutsche Bank AG grew its position in shares of Histogenics by 71.1% during the fourth quarter. Deutsche Bank AG now owns 71,706 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 29,806 shares in the last quarter. Finally, Virtu Financial LLC grew its position in shares of Histogenics by 413.4% during the fourth quarter. Virtu Financial LLC now owns 63,563 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 51,182 shares in the last quarter. Hedge funds and other institutional investors own 48.12% of the company’s stock.
Histogenics Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.